Skip to main content
. 2022 Mar 11;6(6):1651–1660. doi: 10.1182/bloodadvances.2021006415

Figure 5.

Figure 5.

Correlation between post-treatment ctDNA levels and patient response. (A) Log-fold change in ctDNA at EOT vs baseline in patients with or without a CR at EOT. (B) Swimlane plot of individual response to treatment showing patients with baseline ctDNA MMPM above and below the median and ctDNA clearance at EOT; P indicates patients who received polatuzumab vedotin. BL, baseline; PR, partial response; SD, stable disease.